Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,373 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,067 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (618)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07161869 | Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III)(POELH-III) | recruiting | — | 250 | Erasmus Medical CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07677774 | GPC3-Targeted PET/CT in Hepatocellular Carcinoma | recruiting | N/A | 40 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07812805 | SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors | recruiting | Phase 1 | 100 | SK Life Science, Inc.INDUSTRY | 2 | Sep 10, 2026 | clinicaltrials |
| NCT07814014 | Real-world Insight Into Systemic Therapies for HCC: Single-center Study(HCC) | recruiting | — | 1,000 | Mansoura UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06597721 | ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours | recruiting | Phase 1 | 210 | Adcendo ApSINDUSTRY | 2 | Sep 9, 2026 | clinicaltrials |
| NCT06696768 | Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer | recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07147231 | Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07272083 | New Diagnostic Criteria in the Evaluation Response to Ablation Treatment of Hepatocellular Carcinoma Nodules(CEUS_LR_TRA) | recruiting | — | 200 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT03715933 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | recruiting | Phase 1 | 411 | Inhibrx Biosciences, IncINDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT06861452 | Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma(SNIPER) | recruiting | Phase 1 / Phase 2 | 9 | EIR Biotherapies s.r.l.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07282912 | Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels(OLIGOMETS) | recruiting | Phase 2 | 54 | Yale UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07805954 | Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma(RASolute 309) | recruiting | Phase 3 | 400 | Revolution Medicines, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07806292 | Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study(ABH-uHCC) | recruiting | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT03608631 | iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation | recruiting | Phase 1 / Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04005690 | Targeted Pathway Inhibition in Patients With Pancreatic Cancer | recruiting | Early Phase 1 | 90 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05372614 | Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene | recruiting | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06364410 | Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors | recruiting | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06526338 | Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone | recruiting | Phase 2 | 315 | Robert C. MartinOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07062055 | BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases | recruiting | Phase 2 | 54 | Shandong Cancer Hospital and InstituteOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07090499 | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors | recruiting | Phase 1 | 540 | PfizerINDUSTRY | 6 | Sep 4, 2026 | clinicaltrials |
| NCT05673148 | Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial | recruiting | Phase 2 | 146 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 3, 2026 | clinicaltrials |
| NCT05677490 | mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | recruiting | Phase 3 | 382 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 3, 2026 | clinicaltrials |
| NCT06811116 | Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial | recruiting | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06921785 | Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma(ARTEMIDE-HCC01) | recruiting | Phase 3 | 1,220 | AstraZenecaINDUSTRY | 20 | Sep 3, 2026 | clinicaltrials |
| NCT06999837 | [68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Modeling.(HIMIKO) | recruiting | N/A | 40 | Nantes University HospitalOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07120295 | Study of Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories | recruiting | Phase 4 | 75 | University of Colorado, DenverOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07446257 | THIO and Cadonilimab in Resectable Hepatocellular Carcinoma | recruiting | Early Phase 1 | 60 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07644559 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer | recruiting | Phase 2 | 180 | Verastem, Inc.INDUSTRY | 3 | Sep 3, 2026 | clinicaltrials |
| NCT07650773 | CHARM Hepatocellular Carcinoma MEA Study | recruiting | — | 4,000 | AstraZenecaINDUSTRY | 7 | Sep 3, 2026 | clinicaltrials |
| NCT07801287 | Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802197 | Neoadjuvant Radiotherapy vs Upfront Surgery in Locally Advanced Proximal Rectal Cancer(PRELUDE) | recruiting | N/A | 100 | Istanbul UniversityOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05080673 | Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps(FORTE) | recruiting | N/A | 9,500 | NRG OncologyOTHER | 2 | Sep 2, 2026 | clinicaltrials |
| NCT05245500 | Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | recruiting | Phase 1 | 336 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05334069 | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | recruiting | — | 2,000 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05868226 | PRE-ISPY Phase I/II Oncology Platform Program(PRE-ISPY) | recruiting | Phase 1 / Phase 2 | 280 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06673017 | PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) | recruiting | Phase 1 | 26 | PanTher TherapeuticsINDUSTRY | 2 | Sep 2, 2026 | clinicaltrials |
| NCT07024615 | A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer | recruiting | Phase 1 | 25 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07143487 | Family Communications After Genetic Testing | recruiting | N/A | 4,186 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 2, 2026 | clinicaltrials |
| NCT07292298 | Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates | recruiting | Phase 2 | 44 | University of Colorado, DenverOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07463248 | PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy | recruiting | Phase 2 | 64 | Wang XinOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07795437 | GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma | recruiting | N/A | 100 | Peking University First HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07795528 | Postoperative Circulating Tumor DNA Monitoring in Stage I-III Driver-Mutant Colon Adenocarcinoma(ADX-DRIVER-CRC) | recruiting | — | 392 | Ruijin HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04172532 | Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05304481 | Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma | recruiting | Phase 2 | 95 | Lukas Biomedical Inc.INDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06294548 | A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC | recruiting | Phase 1 / Phase 2 | 45 | University of Alabama at BirminghamOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06621472 | Retrolaminar Block Versus Subcostal Transversus Abdominis Plane Block in Liver Resection Surgery | recruiting | N/A | 90 | Cairo UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07381660 | SBRT Versus Surgical Resection for Small HCC | recruiting | Phase 3 | 390 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07636148 | Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance(PreciseOnco) | recruiting | — | 2,000 | Mark C Burgmans, MD PhDOTHER | 2 | Sep 1, 2026 | clinicaltrials |
| NCT02107105 | Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer | recruiting | — | 430 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
Data updated 20 days agoSource updated Sep 10, 2026source: clinicaltrials